PRF Receives Nasdaq Delisting Determination, Requests Hearing to Stay Suspension
PRFX is trading near its 52-week low of $0.641 (15% above the low) on light trading volume (0.2× avg).
Summary
Nasdaq issued a delisting determination on November 9 after PRFX traded below $1.00 for 30 consecutive business days, and the prior reverse split blocks the standard cure period. PRF has requested a hearing, which stays any suspension while it argues for up to 180 more days — until May 8, 2027 — to regain compliance.
Key Events · Legal and Risk Events · PRFX
-
Nasdaq Issues Delisting Determination
The closing bid was below US$1.00 per share for 30 consecutive business days, from September 24, 2026 through November 4, 2026, breaching Listing Rule 5550(a)(2).
-
Prior Reverse Split Blocks Cure Period
Because PRF effected a 1-for-5 reverse share split on February 6, 2026, Rule 5810(c)(3)(A)(iv) makes it ineligible for the normal 180-calendar-day compliance period.
-
Hearing Request Stays Delisting
The company timely requested a hearing before November 16, 2026; the request stays suspension and delisting, and PRFX continues trading on the Nasdaq Capital Market pending the Panel's decision.
-
Panel Could Allow Until May 2027
The Panel has discretion to grant an exception of up to 180 days from the determination, or until May 8, 2027, to regain compliance; the plan may include another reverse share split.
Analysis · PRFX · Life Sciences
Nasdaq moved to delist PRFX after the bid stayed under $1.00 for 30 straight business days, from September 24 to November 4, 2026, and the February 6, 2026 1-for-5 reverse split disqualifies the company from the usual 180-day cure window. The hearing request buys time: suspension is stayed and shares keep trading while a Panel weighs the case, with discretion to allow until May 8, 2027 to regain compliance. Management's pitch rests on roughly $11.0M of cash and short-term deposits at September 30, 2026 and a Phase 2 OcuRing-K enrollment start before year-end, but the likely fix is another reverse split, which would once again reset the share count without addressing the underlying bid weakness. Failure at the Panel means loss of Nasdaq liquidity and a harder path to raising capital, against a backdrop of an activist campaign pressing to replace most of the board.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.64 to $7.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.